Axol Bioscience–StrataStem: drug development technology, 202306– collab excl combining patient samples with iPSC technology for Alzheimer RnD

	Period	2023-06-07
	Partner, 1st	Axol Bioscience Ltd.
	Group	Axol Bioscience (Group)
	Partner, 2nd	StrataStem Ltd.
	Product	drug development technology
	Product 2	iPSC technology (induced pluripotent stem cell technology)

Axol Bioscience Ltd.. (6/7/23). "Press Release: Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease". Cambridge, Edinburgh & Alderley Park.

Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.

Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples. Harnessing its stem cell expertise, Axol will reprogram these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a wide range of brain cells, including neurons and neuroinflammatory cells. Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients - to create a ‘clinical trial in a dish’.

Seeking to accelerate the search for effective treatments of AD, the work specifically focuses on sporadic AD (sAD), the most common form of the disease accounting for over 95% of all cases. sAD has no specific family link and is caused by a combination of genetics, the environment and a person's lifestyle. StrataStem’s collection of donor materials, including fibroblasts and blood samples, has been obtained from fully consenting sAD patients and healthy donors. All materials are supported with extensive longitudinal data on disease state, medical and lifestyle history, and family health summaries. Through the creation of iPSCs and resulting differentiated brain cells from this large-scale Alzheimer’s cohort, Axol aims to enable patient stratification prior to clinical trials for AD treatments, allowing drug discovery companies to select the most responsive patients for trial. Axol’s in vitro approach offers an effective alternative to existing in vivo methods, with the potential to reduce the risk, costs, and timelines of drug discovery and development for AD, with more relevant models of disease.

Liam Taylor, CEO, Axol Bioscience, said: “Here at Axol, we are committed to using iPSCs to make better in vitro models of human disease, expanding our understanding and de-risk drug development. This exclusive agreement with StrataStem is a major strategic move for Axol, bringing us to the forefront of AD drug discovery and development. By commercializing this extensive iPSC library, our drug discovery customers can easily access in vitro models for sAD and interrogate potential mechanisms of the disease more fully.

“Patient stratification at the preclinical stage of drug development is an exciting concept, and we are proud to be among the first to actively source panels of patient samples with comprehensive longitudinal data to do this.”

Chris Ward, CSO and Co-founder, StrataStem, added: “We are delighted to be entering this collaboration with the team at Axol. The recent US Federal Food and Drug Administration Agency (FDA) Modernization Act 2.0 has paved the way for the use of cell-based assays to investigate drug safety and efficacy, including this innovative ‘clinical trial in a dish’ approach. We expect this advancement to de-risk drug development and expedite the process, while also providing valuable cost and time savings.

“We are indebted to the patients who continue to support us in advancing our understanding of AD towards the development of more effective treatments. Our collaboration with Axol will massively accelerate this process and enable researchers to better understand how and why the disease develops, help improve the accuracy of diagnosis and will undoubtedly identify new therapeutics for the treatment of the disease.”

For more information on Axol, please visit https://axolbio.com/axol-stratastem-announcement/

ENDS

Liam Taylor,
CEO, Axol Bioscience

Chris Ward,
Co-founder and CSO, StrataStem

For high-resolution images please contact Zyme Communications.

Zyme Communications
Sarah Jeffery
Tel: +44 (0) 7771 730 919
E-mail: sarah.jeffery@zymecommunications.com

About Axol Bioscience www.axolbio.com

Axol Bioscience is the leading provider of human iPSC-based products and services, to build more relevant models of human disease that expand understanding and de-risk drug development. We support researchers and the biopharma industry with three main offerings: a commercial library of 70 human iPSCs (axoLines™); iPSC-derived cells (axoCells™); and custom research capabilities (axoServices™) comprising gene editing, electrophysiology, reprogramming and differentiation.

At Axol, we've built a reputation for quality and consistency, manufacturing our products under stringent ISO 9001:2015 quality measures with robust scientific expertise and functional data. With over a decade of scientific expertise, a strong company culture and a global network of collaborators, we've become the industry leaders in using human iPSCs to drive better human disease models.

Follow Axol Bioscience on Twitter @axolbio and LinkedIn @Axol Bioscience Ltd

About StrataStem www.stratastem.com

StrataStem is a research-led biotechnology company working to develop disease relevant phenotype-genotype drug development and diagnostic offerings. The company’s activities are targeted at difficult to diagnose and treat neurological conditions. We put patients at the heart of our research, seeking to create representative disease-in-a-dish cell models. This allows us to generate, with greater levels of sensitivity and selectivity, in vitro discovery platforms that uniquely includes genotype and phenotype data. We combine this with machine learning models to identify molecular markers that drive disease onset and progression. Our goal is to target the right patient with the right therapeutic at the right time.

Follow StrataStem on Twitter @StrataStem and LinkedIn @STRATASTEM LIMITED